Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,867 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04906395 | Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer(OVELIA) | active not recruiting | Phase 3 | 250 | Tolmar Inc.INDUSTRY | 7 | Sep 29, 2026 | clinicaltrials |
| NCT05038735 | Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.(EPIK-B5) | active not recruiting | Phase 3 | 210 | Novartis PharmaceuticalsINDUSTRY |
| 17 |
| Sep 29, 2026 |
| clinicaltrials |
| NCT05132582 | A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer(HER2CLIMB-05) | active not recruiting | Phase 3 | 654 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 23 | Sep 29, 2026 | clinicaltrials |
| NCT05296798 | A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | active not recruiting | Phase 3 | 922 | Hoffmann-La RocheINDUSTRY | 29 | Sep 29, 2026 | clinicaltrials |
| NCT04874038 | Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN) | active not recruiting | Phase 3 | 1,604 | University Health Network, TorontoOTHER | 3 | Sep 25, 2026 | clinicaltrials |
| NCT06447623 | Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer | active not recruiting | Phase 3 | 184 | Fudan UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06018337 | A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | active not recruiting | Phase 3 | 541 | DualityBio Inc.INDUSTRY | 17 | Sep 24, 2026 | clinicaltrials |
| NCT04715958 | SHAPE Neoadjuvant Chemotherapy Response | active not recruiting | Phase 2 / Phase 3 | 122 | Kibo NamOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04989504 | Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy | active not recruiting | Phase 3 | 216 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03701334 | A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer(NATALEE) | active not recruiting | Phase 3 | 5,101 | Novartis PharmaceuticalsINDUSTRY | 20 | Sep 18, 2026 | clinicaltrials |
| NCT00099437 | Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.(CONFIRM) | active not recruiting | Phase 3 | 736 | AstraZenecaINDUSTRY | 17 | Sep 14, 2026 | clinicaltrials |
| NCT06500455 | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | active not recruiting | Phase 3 | 274 | NRG OncologyOTHER | 4 | Sep 14, 2026 | clinicaltrials |
| NCT04191499 | A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer(INAVO120) | active not recruiting | Phase 2 / Phase 3 | 325 | Hoffmann-La RocheINDUSTRY | 28 | Sep 11, 2026 | clinicaltrials |
| NCT06561607 | A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer | active not recruiting | Phase 3 | 542 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06057610 | A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer | active not recruiting | Phase 3 | 868 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT00310180 | Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)(TAILORx) | active not recruiting | Phase 3 | 10,273 | National Cancer Institute (NCI)NIH | 8 | Sep 8, 2026 | clinicaltrials |
| NCT04873362 | A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy(Astefania) | active not recruiting | Phase 3 | 1,188 | Hoffmann-La RocheINDUSTRY | 32 | Sep 3, 2026 | clinicaltrials |
| NCT02750826 | Breast Cancer WEight Loss Study (BWEL Study) | active not recruiting | Phase 3 | 3,177 | Alliance for Clinical Trials in OncologyOTHER | 4 | Sep 2, 2026 | clinicaltrials |
| NCT04540692 | Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer(NEOSAMBA) | active not recruiting | Phase 3 | 446 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT01901094 | Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy | active not recruiting | Phase 3 | 2,012 | Alliance for Clinical Trials in OncologyOTHER | 3 | Aug 31, 2026 | clinicaltrials |
| NCT02954874 | Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | active not recruiting | Phase 3 | 1,195 | National Cancer Institute (NCI)NIH | 3 | Aug 31, 2026 | clinicaltrials |
| NCT00070564 | S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer | active not recruiting | Phase 3 | 3,294 | SWOG Cancer Research NetworkNETWORK | 3 | Aug 28, 2026 | clinicaltrials |
| NCT00433511 | Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer | active not recruiting | Phase 3 | 4,994 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2026 | clinicaltrials |
| NCT01272037 | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | active not recruiting | Phase 3 | 5,018 | National Cancer Institute (NCI)NIH | 10 | Aug 28, 2026 | clinicaltrials |
| NCT06144944 | Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer | active not recruiting | Phase 3 | 160 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT03980054 | A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer | active not recruiting | Phase 3 | 2,135 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06635447 | Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients(CAPItrue) | active not recruiting | Phase 3 | 293 | AstraZenecaINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06016738 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer(OPERA-01) | active not recruiting | Phase 3 | 510 | Olema Pharmaceuticals, Inc.INDUSTRY | 26 | Aug 13, 2026 | clinicaltrials |
| NCT04739761 | A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer(DESTINY-B12) | active not recruiting | Phase 3 | 506 | AstraZenecaINDUSTRY | 18 | Aug 11, 2026 | clinicaltrials |
| NCT05113251 | Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer | active not recruiting | Phase 3 | 927 | AstraZenecaINDUSTRY | 18 | Aug 11, 2026 | clinicaltrials |
| NCT06680921 | A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) | active not recruiting | Phase 3 | 482 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05952557 | An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)(CAMBRIA-2) | active not recruiting | Phase 3 | 5,511 | AstraZenecaINDUSTRY | 44 | Aug 10, 2026 | clinicaltrials |
| NCT05814354 | SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial | active not recruiting | Phase 3 | 551 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT02115282 | Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic | active not recruiting | Phase 3 | 608 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT03351348 | Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control | active not recruiting | Phase 3 | 165 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06419621 | PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC | active not recruiting | Phase 3 | 392 | Biotheus Inc.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT02445391 | Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | active not recruiting | Phase 3 | 415 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Jul 27, 2026 | clinicaltrials |
| NCT03975647 | A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | active not recruiting | Phase 3 | 466 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 20 | Jul 23, 2026 | clinicaltrials |
| NCT06316531 | A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer | active not recruiting | Phase 3 | 274 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06382142 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02) | active not recruiting | Phase 3 | 418 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04158362 | Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer(AMBRE) | active not recruiting | Phase 3 | 180 | UNICANCEROTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04895358 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | active not recruiting | Phase 3 | 342 | Merck Sharp & Dohme LLCINDUSTRY | 31 | Jul 22, 2026 | clinicaltrials |
| NCT04975308 | A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer(EMBER-3) | active not recruiting | Phase 3 | 874 | Eli Lilly and CompanyINDUSTRY | 22 | Jul 22, 2026 | clinicaltrials |
| NCT05552001 | Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer(ISIdE) | active not recruiting | Phase 3 | 96 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT02032823 | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer(OlympiA) | active not recruiting | Phase 3 | 1,837 | AstraZenecaINDUSTRY | 24 | Jul 14, 2026 | clinicaltrials |
| NCT07386938 | A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer | active not recruiting | Phase 3 | 246 | R-PharmINDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06112379 | A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | active not recruiting | Phase 3 | 1,902 | AstraZenecaINDUSTRY | 26 | Jul 13, 2026 | clinicaltrials |
Data updated 21 hours agoSource updated Sep 29, 2026source: clinicaltrials